Development of a subunit vaccine for
contagious bovine pleuropneumonia in Africa
Jan Naessens
ILRI BioSciences Day, Nairob...
Funding body: IDRC-CIDA (CIFSFR grant)
Full Title: Development of a subunit vaccine for
contagious bovine pleuropneumonia ...
Important to ILRI: contribute to the following CGIAR
goal and priorities “Animal health research to develop
low-cost vacci...
State of the problem?

One of the most important
livestock diseases in Africa
(AU-IBAR, OIE)
Affects 24 m people in low
in...
How will this project change the outcomes?
A vaccine will reduce the cost of cattle farming and help
to reduce trade restr...
Links to ILRI’s SLO’s?
- Reduced rural poverty for the livestock keepers

- Improved food security, as more livestock prod...
Hypothesis
Antibodies to proteins from mycoplasma can protect
Approach
Use bio-informatics to select 75 potential vaccine
antigens (mycoplasma molecules that are secreted or
present on...
Innovation?
Systemic approach

Direct result
% animals
with symptoms
Non-immunized
Live vaccine
Heat-inactivated
Formalin-fixed

70
13
38
57

average lung
lesion score...
Conclusions:

1. It is possible to induce protection with inactivated
material. Live mycoplasma are not necessary.
2. Prot...
Exp.

1
2
3

Number
ags cattle
25
25
16

60
60
50

date first
immunization
03-10-2013
09-12-2013
04-02-2014

date
challeng...
Future steps?

If we find that a pool of proteins protect:
- confirm & identify protein
- optimize delivery - adjuvant/dos...
What support do you expect from ILRI and the BioScience
Directorate?

I did not expect directorate to do much
but I hope t...
better lives through livestock
ilri-org
Upcoming SlideShare
Loading in …5
×

Development of a subunit vaccine for contagious bovine pleuropneumonia in Africa

726 views

Published on

Presented by Jan Naessens at the ILRI BioSciences Day, Nairobi, 27 November 2013



Published in: Technology, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
726
On SlideShare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
22
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • There MUST be a CGIAR logo or a CRP logo. You can copy and paste the logo you need from the final slide of this presentation. Then you can delete that final slide To replace a photo above, copy and paste this link in your browser: http://www.flickr.com/photos/ilri/sets/72157632057087650/detail/ Find a photo you like and the right size, copy and paste it in the block above.
  • Development of a subunit vaccine for contagious bovine pleuropneumonia in Africa

    1. 1. Development of a subunit vaccine for contagious bovine pleuropneumonia in Africa Jan Naessens ILRI BioSciences Day, Nairobi, 27 November 2013
    2. 2. Funding body: IDRC-CIDA (CIFSFR grant) Full Title: Development of a subunit vaccine for contagious bovine pleuropneumonia in Africa. Short Title: Vaccine for CBPP Institutes: VIDO, Saskatoon KARI Vet Res Centre, Muguga KARI Biotech, Nairobi ILRI, Nairobi
    3. 3. Important to ILRI: contribute to the following CGIAR goal and priorities “Animal health research to develop low-cost vaccines and diagnostic tools appropriate for smallholders” Recipients of outcome: contribution to a better vaccine will directly benefit livestock keepers in areas with CBPP and national veterinary services that are responsible for disease monitoring and vaccination Howe will it change their lives? Better productivity, reduced trade restrictions.
    4. 4. State of the problem? One of the most important livestock diseases in Africa (AU-IBAR, OIE) Affects 24 m people in low income countries Cost? Distribution of CBPP in Africa
    5. 5. How will this project change the outcomes? A vaccine will reduce the cost of cattle farming and help to reduce trade restrictions.
    6. 6. Links to ILRI’s SLO’s? - Reduced rural poverty for the livestock keepers - Improved food security, as more livestock products are available at lower cost
    7. 7. Hypothesis Antibodies to proteins from mycoplasma can protect
    8. 8. Approach Use bio-informatics to select 75 potential vaccine antigens (mycoplasma molecules that are secreted or present on the surface) Produce the recombinant proteins Use these proteins to immunize cattle and check their capacity to protect the host after challenge.
    9. 9. Innovation? Systemic approach Direct result
    10. 10. % animals with symptoms Non-immunized Live vaccine Heat-inactivated Formalin-fixed 70 13 38 57 average lung lesion score 1.3 (± 0.9) 0.3 (± 0.7) 0.5 (± 0.7) 2.0 (± 2.3)
    11. 11. Conclusions: 1. It is possible to induce protection with inactivated material. Live mycoplasma are not necessary. 2. Protection is not correlated with antibody titre against whole mycoplasma. 3. The way the antigen is presented and delivered plays a major role.
    12. 12. Exp. 1 2 3 Number ags cattle 25 25 16 60 60 50 date first immunization 03-10-2013 09-12-2013 04-02-2014 date challenge 07-11-2013 14-01-2014 18-03-2014 end 01-2014 03-2014 05-2014
    13. 13. Future steps? If we find that a pool of proteins protect: - confirm & identify protein - optimize delivery - adjuvant/doses - period of immunity - efficacy - minimum dose If we have a potential vaccine: - roll out and adoption strategy (IDRC-funding) (together with pox virus project - OVI/Alberta)
    14. 14. What support do you expect from ILRI and the BioScience Directorate? I did not expect directorate to do much but I hope they support to continue this project to the end
    15. 15. better lives through livestock ilri-org

    ×